Management of cutaneous disorders related to inflammatory bowel disease

Annals of Gastroenterology

Volumn 25, Issue 1, 2012, Pages 21-36

  Pellicer, Zaira ^a   Santiago, Jesus Manuel ^b   Rodriguez, Alejandro ^b   Alonso, Vicent ^a   Antón, Rosario ^b   Bosca, Marta Maia ^b  

^a Dermatology Department of the University Clinic Hospital of Valencia   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Inflammatory bowel disease; Skin disorders; Treatment

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BENZOYL PEROXIDE; BETAMETHASONE; BIOLOGICAL PRODUCT; COLCHICINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DAPSONE; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LIDOCAINE; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PIMECROLIMUS; POTASSIUM IODIDE; SALICYLIC ACID; SULFADIAZINE SILVER; TACROLIMUS; THALIDOMIDE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; VITAMIN; ZINC;

ACNE; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ALLERGY; ALOPECIA; AMYLOIDOSIS; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; APHTHOUS STOMATITIS; BASAL CELL CARCINOMA; BOWEN DISEASE; BULLOUS PEMPHIGOID; CELLULITIS; CLINICAL FEATURE; CROHN DISEASE; CUTANEOUS POLYARTERITIS NODOSA; DERMATITIS; DISEASE COURSE; DRUG ERUPTION; DRUG MEGADOSE; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; EDEMA; ENTERITIS; EPIDERMOLYSIS BULLOSA ACQUISITA; ERYSIPELAS; ERYTHEMA; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; EXFOLIATIVE DERMATITIS; FOLLICULITIS; GINGIVA HYPERPLASIA; GYNECOMASTIA; HAIR LOSS; HIRSUTISM; HUMAN; HYPERTRICHOSIS; IRON DEFICIENCY; KAPOSI SARCOMA; KERATOSIS; LINEAR IGA BULLOUS DISEASE; LUPUS LIKE SYNDROME; LYMPHADENOPATHY; LYMPHEDEMA; LYMPHOPROLIFERATIVE DISEASE; MALABSORPTION; MALNUTRITION; MERKEL CELL TUMOR; METASTATIC CROHN DISEASE; MYXEDEMA; NAIL DISEASE; OROFACIAL CROHN DISEASE; OROFACIAL ULCERATIVE COLITIS; PIGMENT DISORDER; PRURITUS; PSORIASIS; PURPURA; PYODERMA GANGRENOSUM; PYODERMATITIS PYOSTOMATITIS VEGETANS; RASH; RAYNAUD PHENOMENON; REVIEW; SKIN BURNING SENSATION; SKIN CANCER; SKIN DISEASE; SKIN LYMPHOMA; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; STRIA; SUPPURATIVE HIDRADENITIS; TOXIC EPIDERMAL NECROLYSIS; ULCERATIVE COLITIS; URTICARIA; VASCULITIS; VITAMIN DEFICIENCY; WOUND HEALING IMPAIRMENT; ZINC DEFICIENCY;

EID: 84856864277     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (224)

1. Kethu SR. Extraintestinal manifestations of inflammatory bowel diseases. J Clin Gastroenterol 2006;40:467-475.
2. Yüksel I, Basar O, Ataseven H, et al. Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis 2009;15:546-550.
3. Georgiou S, Pasmatzi E, Monastirli A, Tsambaos D. Cutaneous manifestations of inflammatory bowel disease. Hosp Chron 2006;1:158-168.
4. Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders. Part II. J Am Acad Dermatol 1992;26:371-383.
5. Pittock S, Drumm B, Fleming P, et al. The oral cavity in Crohn's disease. J Pediatr 2001;138:767-771.
6. Rowland M, Fleming P, Bourke B. Looking in the mouth for Crohn ́s disease. Inflamm Bowel Dis 2010;16:332-337.
7. Palamaras I, El-Jabbour J, Pietropaolo N, et al. Metastatic Crohn's disease: a review. JEADV 2008;22:1033-1043.
8. Plauth M, Jenss H, Meyle J. Oral manifestations of Crohn's disease. An analysis of 79 cases. J Clin Gastroenterol 1991;13:29-37.
9. Fatahzadeh M, Schwartz RA, Kapila R, Rochford C. Orofacial Crohn's disease: an oral enigma. Acta Dermatovenerol Croat 2009;17:289-300.
10. Quezada S, Turner PL, Alexiev B, Daly B, Cross R. Severe refractory orofacial Crohn's disease: report of a case. Dig Dis Sci 2009;54:2290-2295.
11. Harty S, Fleming P, Rowland M, et al. A prospective study of the oral manifestations of Crohn's disease. Clin Gastroenterol Hepatol 2005;3:886-891.
12. White A, Nunes C, Escudier M, et al. Improvement in orofacial granulomatosis on a cinnamon- and benzoate-free diet. Inflamm Bowel Dis 2006;12:508-514.
13. Bressler B, Sands BE. Review article: medical therapy for fistulizing Crohn's disease. Aliment Pharmacol Ther 2006;24:1283-1293.
14. Brunner B, Hirschi C, Weimann R, et al. Treatment-resistant lingual Crohn's disease disappears after infliximab. Scand J Gastroenterol 2005;40:1255-1259.
15. Mahadevan U, Sandborn WJ. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis 2001;7:38-42.
16. Doherty G, Kalachand R, Patchett S. Adalimumab as therapy for fistulizing orofacial Crohn's disease. Inflamm Bowel Dis 2010;16:184-185.
17. Ploysangam T, Heubi JE, Eisen D, Balistreri WF, Lucky AW. Cutaneous Crohn's disease in children. J Am Acad Dermatol 1997;36:697-704.
18. Yu JTHT, Chong LY, Lee KC. Metastatic Crohn's disease in a Chinese girl. Hong Kong Med J 2006;12:467-469.
19. Farhi D, Duriez P, Aractingi S, Cosnes J, Khosrotehrani K. Misleading pustular plaques of the lower limbs during Crohn ́s disease: two cases reports. J Med Case Reports 2007;1:109-112.
20. González Gómez JM, Sierra Salinas C, Alonso UsabiagaI, Barco Gálvez A, del Ri ́o Mapelli L, Garci ́a Lorenzo C. Enfermedad de Crohn metastásica. An Esp Pediatr 2001;55:165-168.
21. Emmanuel PO, Phelps RG. Metastatic Crohn ́s disease: a histopathologic study of 12 cases. J Cutan Pathol 2008;35:457-461.
22. Delgado J, Delgado B, Cagnano E, Sperber AD, Fich A. Presentation of Crohn ́s disease as metastatic cutaneous non-caseating granulomatous lesions. IMAJ 2003;5:897-898.
23. Graham DB, Jafer DL, Borum ML. Metastatic Crohn ́s disease of the face. Dig Dis Sci 2006;51:2062-2063.
24. Goyal A, Mansel RE, Young HL, Douglas-Jones A. Metastatic cutaneous Crohn ́s disease of the nipple: report of a case. Dis Colon Rectum 2006;49:1324.
25. Staines KS, Green R, Felix DH. The management of fistulizing oral Crohn's disease with infliximab. J Oral Pathol Med 2007;36:444-446.
26. Eames T, Landthaler M, Karrer S. Crohn ́s disease: an important differential diagnosis of granulomatous skin diseases. Eur J Dermatol 2009;19:360-364.
27. Guest GD, Fink RL. Metastatic Crohn ́s disease: case report of an unusual variant and review of the literature. Dis Colon Rectum 2000;43:1764-1766.
28. Kafity AA, Pellegrini AE, Fromkes JJ. Metastatic Crohn ́s disease. A rare cutaneous manifestation. J Clin Gastroenterol 1993;17:300-303.
29. McGillis ST, Huntley AC. Metastatic Crohn ́s disease. West J Med 1989;151:203-205.
30. Gilson MR, Elston LC, Pruitt CA. Metastatic Crohn ́s disease: remission induced by mesalamine and prednisone. J Am Acad Dermatol 1999;41:476-479.
31. Carranza DC, Young L. Successful treatment of metastatic Crohn ́s disease with cyclosporine. J Drugs Dermatol 2008;7:789-791.
32. Sierra C, Barco A, del Río L. Treatment of metastatic Crohn ́s disease. J Pediatr Gastroenterol Nutr 2002;35:708-709.
33. Casson DH, Eltumi M, Tomlin S, Walker-Smith JA, Murch SH. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000;47:436-440.
34. Van Dullemen HM, de Jong E, Slors F, Tytgat GN, van Deventer SJ. Treatment of therapy-resistant perineal metastatic Crohn's disease after proctectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2: Report of two cases. Dis Colon Rectum 1998;41:98-102.
35. Miller AM, Elliott PR, Fink R, Connell W. Rapid response of severe refractory metastatic Crohn's disease to infliximab. J Gastroenterol Hepatol 2001;16:940-942.
36. Escher JC, Stoof TJ, van Deventer SJ, van Furth AM. Successful treatment of metastatic Crohn disease with infliximab. J Pediatr Gastroenterol Nutr 2002;34:420-423.
37. Rispo A, Lembo G, Insabato L, Cozzolino A, Pesce G, Castiglione F. Successful treatment of therapy-resistant metastatic Crohn's disease with infliximab. Br J Dermatol 2004;150:1045-1046.
38. Graham DB, Jager DL, Borum ML. Metastatic Crohn's disease of the face. Dig Dis Sci 2006;51:2062-2063.
39. Konrad A, Seibold F. Response of cutaneous Crohn's disease to infliximab and methotrexate. Dig Liver Dis 2003;35:351-356.
40. Martín de Carpi J, Chávez Caraza K, Vicente Villa MA, González Ensenat MA, Vilar Escrigas P, Vila Miravet V. Manifestaciones cutáneas de la enfermedad inflamatoria intestinal. An Pediatr 2009;70:570-577.
41. Petrolati A, Altavilla N, Cipolla R, et al.Cutaneous Metastatic Crohn ́s Disease Responsive to Infliximab. Am J Gastroenterol 2009;104:1058-1059.
42. Makhija S, Trotter M, Wagner E, Coderre S, Panaccione R. Refractory Crohn ́s disease of the vulva treated with infliximab: a case report. Can J Gastroenterol 2007;21:835-837.
43. Van der Velden JJ, van Marion AM, Kremer B, Straetmans JM, Henquet CJ, Frank J. Erythema nodosum as an early sign of Crohn's disease. Int J Dermatol 2007;46 Suppl.3:27-29.
44. Requena L, Sánchez Yus E. Erythema nodosum. Semin Cutan Med Surg 2007;26:114-125.
45. Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders. Part II. J Am Acad Dermatol 1992;26:371-383.
46. Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol 2008;26:265-273.
47. Mana J, Marcoval J. Erythema nodosum. Clin Dermatol 2007;25:288-294.
48. Gilchrist H, Patterson JW. Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management. Dermatol Ther 2010;23:320-327.
49. Schwartz RA, Nervi SJ. Erythema nodosum: a sign of systemic disease. Am Fam Physician 2007;75:695-700.
50. Tavarela Veloso F. Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther 2004;20 Suppl 4:50-53.
51. Schmidt KJ, Fellermann K, Wellhöner P, et al. Clinical trial: cyclophosphamide pulse therapy - a promising therapeutic alternative in refractory Crohn's disease. Aliment Pharmacol Ther 2009;29:1230-1239.
52. Goudet P, Dozois RR, Kelly KA, Ilstrup DM, Phillips SF. Characteristics and evolution of extraintestinal manifestations associated with ulcerative colitis after proctocolectomy. Dig Surg 2001;18:51-55.
53. Fukunaga K, Sawada K, Fukuda Y, et al. Extracorporeal monocyte granulocytapheresis was effective for a patient of erythema nodosum concomitant with ulcerative colitis. Ther Apher Dial 2003;7:122-126.
54. Conrad C, Trüeb RM. Pyoderma gangrenosum. J Dtsch Dermatol Ges 2005;3:334-342.
55. Cohen PR. Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol 2009;10:301-312.
56. Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009;23:1008-1017.
57. Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010;62:646-654.
58. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005;53:273-283.
59. Ahmadi S, Powell FC. Pyoderma gangrenosum: uncommon presentations. Clin Dermatol 2005;23:612-620.
60. Wollina U. Pyoderma gangrenosum--a review. Orphanet J Rare Dis 2007;2:19.
61. Saigal R, Singh Y, Mittal M, Kansal A, Maharia HR. Pyoderma gangrenosum. J Assoc Physicians India 2010;58:378-383.
62. Bhat RM. Management of pyoderma gangrenosum--an update. Indian J Dermatol Venereol Leprol 2004;70:329-335.
63. Wollina U, Karamfilov T. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol Venereol 2000;14:187-190.
64. Lyon CC, Smith AJ, Beck MH, Wong GA, Griffiths CE. Parastomal pyoderma gangrenosum: clinical features and management. J Am Acad Dermatol 2000;42:992-1002.
65. Rozen SM, Nahabedian MY, Manson PN. Management strategies for pyoderma gangrenosum: case studies and review of literature. Ann Plast Surg 2001;47:310-315.
66. Kim TY, Han DS, Eun CS, Chung YW. Recombinant human epidermal growth factor enhances wound healing of pyoderma gangrenosum in a patient with ulcerative colitis. Inflamm Bowel Dis 2008;14:725-727.
67. Chow RK, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996;34:1047-1060.
68. Wenzel J, Gerdsen R, Phillipp-Dormston W, Bieber T, Uerlich M. Topical treatment of pyoderma gangraenosum. Dermatology 2002;205:221-223.
69. Aseni P, Di Sandro S, Mihaylov P, Lamperti L, De Carlis LG. Atypical presentation of pioderma gangrenosum complicating ulcerative colitis: rapid disappearance with methylprednisolone. World J Gastroenterol 2008;14:5471-5473.
70. Friedman S, Marion JF, Scherl E, Rubin PH, Present DH. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001;7:1-7.
71. Schöfer H, Baur S. Successful treatment of postoperative pyoderma gangrenosum with cyclosporin. J Eur Acad Dermatol Venereol 2002;16:148-151.
72. Baumgart DC, Wiedenmann B, Dignass AU. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis. Inflamm Bowel Dis 2004;10:421-424.
73. Hasselmann DO, Bens G, Tilgen W, Reichrath J. Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature. J Dtsch Dermatol Ges 2007;5:560-564.
74. Fujimoto E, Fujimoto N, Kuroda K, Tajima S. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol 2004;151:1090-1092.
75. Reguiaï Z, Grange F. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease. Am J Clin Dermatol 2007;8:67-77.
76. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-333.
77. Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1424-1429.
78. Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. Inflamm Bowel Dis 2009;15:803-806.
79. Juillerat P, Mottet C, Pittet V, et al. Extraintestinal manifestations of Crohn's disease. Digestion 2007;76:141-148.
80. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006;55:505-509.
81. Kouklakis G, Moschos J, Leontiadis GI, et al. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report. Rom J Gastroenterol 2005;14:401-403.
82. Ermis F, Ozdil S, Akyüz F, Pinarbasi B, Mungan Z. Pyoderma gangrenosum treated with infliximab in inactive ulcerative colitis. Inflamm Bowel Dis 2008;14:1611-1613.
83. Gelber AC. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;363:1086.
84. Tada M, Nakanishi T, Hirata C, et al. Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis. Mod Rheumatol 2010;20:598-601.
85. Chia M W, Teo L, Tay YK, Poh WT. Pustular pyoderma gangrenosum: an uncommon variant which is easily misdiagnosed. Dermatol Online J 2008;14:21.
86. Badgwell C, Rosen T. Penile pyoderma gangrenosum. Dermatol Online J 2006;12:8.
87. Scarfe WC. "All that glitters is not gold": standards for cone-beam computerized tomographic imaging. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111:402-408.
88. Lourenço SV, Hussein TP, Bologna SB, Sipahi AM, Nico MM. Oral manifestations of inflammatory bowel disease: a review based on the observation of six cases. J Eur Acad Dermatol Venereol 2010;24:204-207.
89. Hegarty AM, Barrett AW, Scully C. Pyostomatitis vegetans. Clin Exp Dermatol 2004;29:1-7.
90. VanHale HM, Rogers RS, Zone JJ, Greipp PR. Pyostomatitis vegetans. A reactive mucosal marker for inflammatory disease of the gut. Arch Dermatol 1985;121:94-98.
91. Konstantopoulou M, O'Dwyer EM, Steele JC, Field EA, Lewis MA, Macfarlane AW. Pyodermatitis-pyostomatitis vegetans complicated by methicillin-resistant Staphylococcus aureus infection. Clin Exp Dermatol 2005;30:666-668.
92. Soriano ML, Martínez N, Grilli R, Fariña MC, Martín L, Requena L. Pyodermatitis-pyostomatitis vegetans: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87:322-326.
93. Storwick GS, Prihoda MB, Fulton RJ, Wood WS. Pyodermatitis-pyostomatitis vegetans: a specific marker for inflammatory bowel disease. J Am Acad Dermatol 1994;31:336-341.
94. Yasuda M, Amano H, Nagai Y, Tamura A, Ishikawa O, Yamaguchi S. Pyodermatitis-pyostomatitis vegetans associated with ulcerative colitis: successful treatment with total colectomy and topical tacrolimus. Dermatology 2008;217:146-148.
95. Bens G, Laharie D, Beylot-Barry M, et al. Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease. Br J Dermatol 2003;149:181-184.
96. Ruiz-Roca JA, Berini-Aytés L, Gay-Escoda C. Pyostomatitis vegetans. Report of two cases and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:447-454.
97. Femiano F, Lanza A, Buonaiuto C, Perillo L, Dell'Ermo A, Cirillo N. Pyostomatitis vegetans: a review of the literature. Med Oral Patol Oral Cir Bucal 2009;14:E114-E117.
98. Calobrisi SD, Mutasim DF, McDonald JS. Pyostomatitis vegetans associated with ulcerative colitis. Temporary clearance with fluocinonide gel and complete remission after colectomy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79:452-454.
99. Paoluzi OA, Crispino P, Amantea A, et al. Diffuse febrile dermatosis in a patient with active ulcerative colitis under treatment with steroids and azathioprine: a case of Sweet's syndrome. Case report and review of literature. Dig Liver Dis 2004;36:361-366.
100. Anglada Pintado JC, Michán Doña A, Silva Abad A, et al. Síndrome de Sweet y enfermedad inflamatoria intestinal. Aportación de un nuevo caso y revisión de la literatura. An Med Interna (Madrid) 2002;19:419-422.
101. Malheiros AP, Teixeira MG, Takahashi MD, de Almeida MG, Kiss DR, Cecconello I. Sweet syndrome associated with ulcerative colitis. Inflamm Bowel Dis 2007;13:1583-1584.
102. Pérez Rodríguez MT, Martínez-Ares D, Martín-Granizo I, Pallarés Peral A. Sweet's syndrome and erythema nodosum in a Crohn's disease patient. Med Clin (Barc) 2007;128:156-157.
103. Catalán-Serra I, Martín-Moraleda L, Navarro-López L, et al. Crohn's disease and Sweet's syndrome: an uncommon association. Rev Esp Enferm Dig 2010;102:331-337.
104. Foster EN, Nguyen KK, Sheikh RA, Prindiville TP. Crohn's disease associated with Sweet's syndrome and Sjögren's syndrome treated with infliximab. Clin Dev Immunol 2005;12:145-149.
105. Cohen PR, Kurzrock R. Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol 2003;42:761-778.
106. Cohen PR, Kurzrock R. Sweet's syndrome: a review of current treatment options. Am J Clin Dermatol 2002;3:117-131.
107. Vij A, Modi GM, Suwattee P, Cockerell CJ, Hsu S. Chronic, recurrent neutrophilic dermatosis: a case report. Dermatol Online J 2010;16:1.
108. Kaur MR, Bazza MA, Ryatt KS. Neutrophilic dermatosis of the dorsal hands treated with indomethacin. Br J Dermatol 2006;155:1089-1090.
109. Smith HR, Ashton RE, Beer TW, Theaker JM. Neutrophil-poor Sweet's syndrome with response to potassium iodide. Br J Dermatol 1998;139:555-556.
110. Ritter S, George R, Serwatka LM, Elston DM. Long-term suppression of chronic Sweet's syndrome with colchicine. J Am Acad Dermatol 2002;47:323-324.
111. Maillard H, Leclech C, Peria P, Avenel-Audran M, Verret JL. Colchicine for Sweet's syndrome. A study of 20 cases. Br J Dermatol 1999;140:565-566.
112. von den Driesch P, Steffan C, Zöbe A, Hornstein OP. Sweet's syndrome--therapy with cyclosporin. Clin Exp Dermatol 1994;19:274-277.
113. Spencer B, Nanavati A, Greene J, Butler DF. Dapsone-responsive histiocytoid Sweet's syndrome associated with Crohn's disease. J Am Acad Dermatol 2008;59(2 Suppl 1):S58-S60.
114. Jeanfils S, Joly P, Young P, Le Corvaisier-Pieto C, Thomine E, Lauret P. Indomethacin treatment of eighteen patients with Sweet's syndrome. J Am Acad Dermatol 1997;36:436-439.
115. Joe EK. Sweet syndrome. Dermatol Online J 2003;9:28.
116. Cohen PR, Holder WR. Pentoxifylline for Sweet's syndrome. J Am Acad Dermatol 1995;32:533-535.
117. Su W P, Fett DL, Gibson LE, Pittelkow MR. Sweet syndrome: acute febrile neutrophilic dermatosis. Semin Dermatol 1995;14:173-178.
118. Delluc A, Limal N, Puéchal X, Francès C, Piette JC, Cacoub P. Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. Ann Rheum Dis 2008;67:278-279.
119. Lear JT, Atherton MT, Byrne J P. Neutrophilic dermatoses: pyoderma gangrenosum and Sweet's syndrome. Postgrad Med J 1997;73:65-68.
120. Joshi RK, Atukorala DN, Abanmi A, al Khamis O, Haleem A. Successful treatment of Sweet's syndrome with doxycycline. Br J Dermatol 1993;128:584-586.
121. Banet DE, McClave SA, Callen J P. Oral metronidazole, an effective treatment for Sweet's syndrome in a patient with associated inflammatory bowel disease. J Rheumatol 1994;21:1766-1768.
122. Rahier JF, Lion L, Dewit O, Lambert M. Regression of Sweet's syndrome associated with Crohn's disease after anti-Tumour Necrosis Factor therapy. Acta Gastroenterol Belg 2005;68:376-379.
123. El-Azhary RA, Brunner KL, Gibson LE. Sweet syndrome as a manifestation of azathioprine hypersensitivity. Mayo Clin Proc 2008;83:1026-1030.
124. Treton X, Joly F, Alves A, Panis Y, Bouhnik Y. Azathioprine-induced Sweet's syndrome in Crohn's disease. Inflamm Bowel Dis 2008;14:1757-1758.
125. Yiasemides E, Thom G. Azathioprine hypersensitivity presenting as a neutrophilic dermatosis in a man with ulcerative colitis. Australas J Dermatol 2009;50:48-51.
126. Daoud MS, Hutton K P, Gibson LE. Cutaneous periarteritis nodosa: a clinicopathological study of 79 cases. Br J Dermatol 1997;136:706-713.
127. Díaz-Pérez JL, De Lagrán ZM, Díaz-Ramón JL, Winkelmann RK. Cutaneous polyarteritis nodosa. Semin Cutan Med Surg 2007;26:77-86.
128. Komatsuda A, Kinoshita K, Togashi M, et al. Cutaneous polyarteritis nodosa in a patient with Crohn's disease. Mod Rheumatol 2008;18:639-642.
129. Matsumara Y, Mizuno K, Okamoto H, Imamura S. A case of cutaneous polyarteritis nodosa associated with ulcerative colitis. Br J Dermatol 2000;142:561-562.
130. Gibson LE. Cutaneous vasculitis: approach to diagnosis and systemic associations. Mayo Clin Proc 1990;65:221-229.
131. Goslen JB, Graham W, Lazarus GS. Cutaneous polyarteritis nodosa. Report of a case associated with Crohn's disease. Arch Dermatol 1983;119:326-329.
132. Uthman I. Pharmacological therapy of vasculitis: an update. Curr Opin Pharmacol 2004;4:177-182.
133. Volk DM, Owen LG. Cutaneous polyarteritis nodosa in a patient with ulcerative colitis. J Pediatr Gastroenterol Nutr 1986;5:970-972.
134. Ray TL, Levine JB, Weiss W, Ward PA. Epidermolysis bullosa acquisita and inflammatory bowel disease. J Am Acad Dermatol 1982;6:242-252.
135. Hughes BR, Horne J. Epidermolysis bullosa acquisita and total ulcerative colitis. J R Soc Med 1988;81:473-475.
136. Chouvet B, Guillet G, Perrot H, Descos L. Acquired epidermolysis bullosa with Crohn's disease. Report of two cases and review of literature. Ann Dermatol Venereol 1982;109:53-63.
137. Gluck M, Kayne A. Acquired epidermolysis bullosa and Crohn's disease. Gastrointest Endosc 2003;57:563-564.
138. Raab B, Fretzin DF, Bronson DM, Scott MJ, Roenigk HH, Medenica M. Epidermolysis bullosa acquisita and inflammatory bowel disease. JAMA 1983;250:1746-1748.
139. Chen M, O'Toole EA, Sanghavi J, et al. The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with crohn's disease have autoantibodies to type VII collagen. J Invest Dermatol 2002;118:1059-1064.
140. Lehman JS, Camilleri MJ, Gibson LE. Epidermolysis bullosa acquisita: concise review and practical considerations. Int J Dermatol 2009;48:227-235.
141. Selby L, De Castro F, De Villiers WJ. The association of bullous pemphigoid and ulcerative colitis. Dig Dis Sci 2004;49:1768-1770.
142. Tripodi G, Risso M, Tenerini L, Gandullia P, Castellano E, Rivabella L. Drug-resistant bullous pemphigoid and inflammatory bowel disease in a pediatric case successfully treated by plasma exchange and extracorporeal photochemotherapy. J Clin Apher 2007;22:26-30.
143. Ahmed AR, Kaplan RP, Hardy D, Feldman E, Pitt H. Bullous pemphigoid and ulcerative colitis. Int J Dermatol 1982;21:594-598.
144. Vaccaro M, D'Amico D, Borgia F, Guarneri F, Cannavò S. Bullous pemphigoid following use of sulphasalazine for ulcerative colitis: drug-induced eruption or true association? Dermatology 2001;203:194-195.
145. Tirado-Sánchez A, Díaz-Molina V, Ponce-Olivera RM. Efficacy and safety of azathioprine and dapsone as an adjuvant in the treatment of bullous pemphigoid. Allergol Immunopathol (Madr) 2011 (in press)
146. Birnie AJ, Perkins W. A case of linear IgA disease occurring in a patient with colonic Crohn's disease. Br J Dermatol 2005;153:1050-1052.
147. Nanda A, Dvorak R, Al-Sabah H, Madda JP, Anim JT, Alsaleh QA. Association of linear IgA bullous disease of childhood with Crohn's disease. Int J Dermatol 2006;45:1184-1186.
148. Keller AS, Bouldin MB, Drage LA, Hauser SC, Davis MD. Linear IgA bullous dermatosis: an association with ulcerative colitis versus renal cell carcinoma. Dig Dis Sci 2003;48:783-789.
149. Egan CA, Zone JJ. Linear IgA bullous dermatosis. Int J Dermatol 1999;38:818-827.
150. Fernández-Guarino M, Sáez EM, Gijón RC, García BP, Olasolo PJ. Linear IGA dermatosis associated with ulcerative colitis. Eur J Dermatol 2006;16:692-693.
151. Kenani N, Mebazaa A, Denguezli M, et al. Childhood linear IgA bullous dermatosis in Tunisia. Pediatr Dermatol 2009;26:28-33.
152. Walker SL, Banerjee P, Harland CC, Black MM. Remission of linear IgA disease associated with ulcerative colitis following panproclocolectomy. Br J Dermatol 2000;143:1341-1342.
153. Torres T, Sanches M, Selores M. Linear IgA bullous disease in a patient with Crohn's disease. Acta Dermatovenerol Alp Panonica Adriat 2010;19:29-31.
154. Taniguchi T, Maejima H, Saito N, Katsuoka K, Haruki S. Case of linear IgA bullous dermatosis-involved ulcerative colitis. Inflamm Bowel Dis 2009;15:1284-1285.
155. Garcia-Zuazaga J, Olbricht SM. Cutaneous squamous cell carcinoma. Adv Dermatol 2008;24:33-57.
156. Frisch M, Johansen C. Anal carcinoma in inflammatory bowel disease. Br J Cancer 2000;83:89-90.
157. O'Connell PR, Dozois RR, Irons GB, Scheithauer BW. Squamous cell carcinoma occurring in a skin-grafted ileostomy stoma. Report of a case. Dis Colon Rectum 1987;30:475-478.
158. Devon KM, Brown CJ, Burnstein M, McLeod RS. Cancer of the anus complicating perianal Crohn's disease. Dis Colon Rectum 2009;52:211-216.
159. Slater G, Greenstein A, Aufses AH. Anal carcinoma in patients with Crohn's disease. Ann Surg 1984;199:348-350.
160. Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010;105:1480-1487.
161. Kang J, Min BS, Lee KY, Jang SJ, Kim WH, Kim NK. Squamous cell carcinoma of the anus in a patient with perianal Crohn's disease. Int J Colorectal Dis 2010;25:411-413.
162. Gurudutt V V, Genden EM. Cutaneous squamous cell carcinoma of the head and neck. J Skin Cancer 2011;2011:502723.
163. Cleary RK, Schaldenbrand JD, Fowler JJ, Schuler JM, Lampman RM. Perianal Bowen's disease and anal intraepithelial neoplasia: review of the literature. Dis Colon Rectum 1999;42:945-951.
164. Sarmiento JM, Wolff BG, Burgart LJ, Frizelle FA, Ilstrup DM. Perianal Bowen's disease: associated tumors, human papillomavirus, surgery, and other controversies. Dis Colon Rectum 1997;40:912-918.
165. Kuhlgatz J, Golas MM, Sander B, Füzesi L, Hermann RM, Miericke B. Human papilloma virus infection in a recurrent squamous cell carcinoma associated with severe Crohn's disease. Inflamm Bowel Dis 2005;11:84-86.
166. Fox L P, Pasternack FR, Geyer AS, Grossman ME. Perineal squamous cell cancer in a patient with fistulizing and ulcerating Crohn's disease. Clin Exp Dermatol 2005;30:718-719.
167. Buchman AL, Ament ME, Doty J. Development of squamous cell carcinoma in chronic perineal sinus and wounds in Crohn's disease. Am J Gastroenterol 1991;86:1829-1832.
168. Seya T, Tanaka N, Shinji S, et al. Squamous cell carcinoma arising from recurrent anal fistula. J Nippon Med Sch 2007;74:319-324.
169. Van der Zee HH, van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol 2010;162:195-197.
170. Koilakou S, Karapiperis D, Tzathas C. A case of hidradenitis suppurativa refractory to anti-TNFalpha therapy in a patient with Crohn's disease. Am J Gastroenterol 2010;105:231-232.
171. Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol 2007;46:1287-1291.
172. Goertz RS, Konturek PC, Naegel A, et al. Experiences with a long-term treatment of a massive gluteal acne inversa with infliximab in Crohn's disease. Med Sci Monit 2009;15:CS14-CS18.
173. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 2005;16:58-61.
174. Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003;49(5 Suppl):S275-276.
175. Roussomoustakaki M, Dimoulios P, Chatzicostas C, et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol 2003;38:1000-1004.
176. Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol 2002;97:2155-2156.
177. Martínez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001;7:323-326.
178. Moul DK, Korman NJ. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 2006;142:1110-1112.
179. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008;158:567-572.
180. Mortimore M, Florin TH. A role for B12 in inflammatory bowel disease patients with suppurative dermatoses? An experience with high dose vitamin B12 therapy. J Crohns Colitis 2010;4:466-470.
181. Bleiziffer O, Dragu A, Kneser U, Horch RE. Solving acne inversa (hidradenitis suppurativa) in Crohn disease with buried chip skin grafts. J Cutan Med Surg 2009;13:164-168.
182. Greenstein AJ, Sachar DB, Panday AK, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 1992;71:261-270.
183. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis 2001;7:295-300.
184. Serra I, Oller B, Mañosa M, Naves JE, Zabana Y, Cabré E. Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome. J Crohns Colitis 2010;4:269-274.
185. Janczewska I, Mejhert M, Hast R, Runarsson G, Sandstedt B. Primary AL-amyloidosis, ulcerative colitis and collagenous colitis in a 57-year-old woman: a case study. Scand J Gastroenterol 2004;39:1306-1309.
186. Seijo Ríos S, Barreiro de Acosta M, Vieites Pérez-Quintela B, et al. Secondary amyloidosis in Crohn's disease. Rev Esp Enferm Dig 2008;100:792-797.
187. Iizuka M, Konno S, Horie Y, Itou H, Shindo K, Watanabe S. Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease. Gut 2006;55:744-745.
188. Verschueren P, Lensen F, Lerut E, et al. Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 2003;62:368-369.
189. Fernández-Nebro A, Ureña I, Irigoyen M V, García-Vicuña R. Anti-TNF-alpha for treatment of amyloidosis associated with Crohn's disease. Gut 2006;55:1666-1667.
190. Boscá MM, Pérez-Baylach CM, Solis MA, et al. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor. Gut 2006;55:294-295.
191. Hatakeyama T, Komatsuda A, Matsuda A, et al. Renal amyloidosis associated with extracapillary glomerulonephritis and vasculitis in a patient with inflammatory bowel disease treated with infliximab. Clin Nephrol 2008;70:240-244.
192. Park YK, Han DS, Eun CS. Systemic amyloidosis with Crohn's disease treated with infliximab. Inf lamm Bowel Dis 2008;14:431-432.
193. Lotti T, Hercogova J, Prignano F. The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities? Dermatol Ther 2010;23:119-122.
194. Kocak E, Ozer E, Filik L. Differential diagnosis of inflammatory bowel diseases in psoriasis. Acta Clin Belg 2010;65:208-209.
195. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003;48:805-821.
196. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 2009;23:561-565.
197. Lee FI, Bellary S V, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990;85:962-963.
198. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000;42:829-830.
199. Andreakos E, Taylor PC, Feldmann M. Monoclonal antibodies in immune and inflammatory diseases. Curr Opin Biotechnol 2002;13:615-620.
200. Kuek A, Hazleman BL, Ostör AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007;83:251-260.
201. Mössner R, Schön M P, Reich K. Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol 2008;26:486-502.
202. De Vries HS, van Oijen MG, Driessen RJ, et al. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol 2011;71:7-19.
203. Karampetsou M P, Liossis SN, Sfikakis P P. TNF-α antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010;103:917-928.
204. Piérard GE, Piérard-Franchimont C, Szepetiuk G, Paquet P, Quatresooz P. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities. Expert Opin Biol Ther 2010;10:1197-1208.
205. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-1094.
206. Schreiber S, Rutgeerts P, Fedorak RN, et al. CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumabpegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-818.
207. Gisondi P, Del Giglio M, Cozzi A, Girolomoni G. Psoriasis, the liver, and the gastrointestinal tract. Dermatol Ther 2010;23:155-159.
208. Cingoz O. Ustekinumab. MAbs 2009;1:216-221.
209. Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther 2010;10:587-604.
210. Scherl EJ, Kumar S, Warren RU. Review of the safety and efficacy of ustekinumab. Therap Adv Gastroenterol 2010;3:321-328.
211. Lin AN. Innovative use of topical calcineurin inhibitors. Dermatol Clin 2010;28:535-545.
212. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4-Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-1252.
213. James DG, Seo DH, Chen J, Vemulapalli C, Stone CD. Efalizumab, a Human Monoclonal Anti-CD11a Antibody, in the Treatment of Moderate to Severe Crohn's Disease: An Open-Label Pilot Study. Dig Dis Sci 2010 (in press)
214. Sehgal VN, Jain S. Acrodermatits enteropathica. Clin Dermatol 2000;18:745-748.
215. Park CH, Lee MJ, Kim HJ, Lee G, Park J W, Cinn Y W. Congenital zinc deficiency from mutations of the SLC39A4 gene as the genetic background of acrodermatitis enteropathica. J Korean Med Sci 2010;25:1818-1820.
216. Medina-Murillo R, Rodríguez-Wong U. Manifestaciones cutáneas de las enfermedades inflamatorias intestinales. Rev Hosp Jua Mex 2007;74:11-15.
217. Mariotti C, Gellera C, Rimoldi M, et al. Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. Neurol Sci 2004;25:130-137.
218. Lexicomp, Inc. Mesalamine,Sulphasalazine, Azathioprine, 6-Mercaptopurine, Methotrexate, Cyclosporine, Systemic steroids, Infliximab, Adalimumab, Ciprofloxacine, Metronidazole, Tacrolimus, Thalidomide, GMCSF: Drug information [Internet] UpToDate, Rose BD (Ed) UpToDate, Walham, MA; 2011 [access June 2011]. Available at: http://www.uptodate.com.
219. Fernández Herrera J, Requena Caballero L. Erupciones Medicamentosas Cutáneas. Área Científica Menarini, Signament Edics 2004.
220. Lee A, Thomson J. Drug-induced Skin Reactions. Chapter 5. Adverse Drug Reactions, 2nd Edition. Pharmaceutical Press 2006
221. Baumgart DC, Grittner U, Steingräber A, Azzaro M, Philipp S. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis 2011;17:2512-2520.
222. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008;9:1-14.
223. Akahoshi K, Chijiwa Y, Kabemura T, Okabe H, Akamine Y, Nawata H. Desensitization for sulfasalazine-induced skin rash in a patient with ulcerative colitis. J Gastroenterol 1994;29:772-775.
224. Katsanos KH, Christodoulou DK, Kitsanou M, Basioukas K, Bai M, Tsianos E V. Perianal condylomata and HPV-negative ileostomal papillomatous lesion in Crohn's disease during Infliximab therapy Ann Gastroenterol 2005;18:80-83.